John L. Berk MD

Published on 10/28/2025

Wixner J, Conceição I, Berk JL, Adams D, Polydefkis MJ, Attarian S, Gillmore JD, Dyck PJB, Chen J, Kwoh TJ, Nåtman J, Zhou W, Cruz MW. Neuropathy impairment and nutritional status with eplontersen in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2025 Oct 28; 1-5. PMID: 41147681.

Published on 8/12/2025

Maurer MS, Berk JL, Damy T, Sheikh FH, González-Costello J, Morbach C, Delgado D, Bondue A, Azevedo O, Poulsen SH, Jankowska EA, Yang L, Bender S, Eraly SA, Jay PY, Vest J, Fontana M. Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B. J Am Coll Cardiol. 2025 Aug 12; 86(6):459-475. PMID: 40769675.

Published on 6/23/2025

Berk JL, Lairez O, Schwartzmann P, Bender S, White MT, Jay PY, Danese D, Witteles R. Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis: Post Hoc Analysis of APOLLO-B. JACC Adv. 2025 Aug; 4(8):101876. PMID: 40555140.

Published on 3/31/2025

Fontana M, Berk JL, Drachman B, Garcia-Pavia P, Hanna M, Lairez O, Witteles R. Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis. Circ Heart Fail. 2025 Aug; 18(8):e012112. PMID: 40160093.

Published on 3/1/2025

Adams D, Wixner J, Polydefkis M, Berk JL, Conceição IM, Dispenzieri A, Peltier A, Ueda M, Bender S, Capocelli K, Jay PY, Yureneva E, Obici L. Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension. JAMA Neurol. 2025 Mar 01; 82(3):228-236. PMID: 39804640.

Published on 2/3/2025

Conceição I, Berk JL, Weiler M, Kowacs PA, Dasgupta NR, Khella S, Chao CC, Attarian S, Kwoh TJ, Jung SW, Chen J, Viney NJ, Yu RZ, Gertz M, Masri A, Cruz MW, Coelho T. Correction: Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform. J Neurol. 2025 Feb 03; 272(2):182. PMID: 39899052.

Published on 11/17/2024

Wixner J, Berk JL, Adams D, Polydefkis M, Conceição I, Attarian S, Gillmore JD, Dyck PJB, Folkvaljon F, Zhou W, Chen J, Viney NJ, Kwoh TJ, Coelho T, Waddington-Cruz M. Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial. Amyloid. 2025 Mar; 32(1):29-38. PMID: 39552152.

Published on 11/17/2024

Folkvaljon F, Gertz M, Gillmore JD, Khella S, Masri A, Maurer MS, Cruz MW, Wixner J, Chen J, Reicher B, Kwoh J, Yarlas A, Berk JL. Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health-Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis. Muscle Nerve. 2025 Jan; 71(1):96-107. PMID: 39552102.

Published on 8/30/2024

Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, Damy T, Garcia-Pavia P, Taubel J, Solomon SD, Sheikh FH, Tahara N, González-Costello J, Tsujita K, Morbach C, Pozsonyi Z, Petrie MC, Delgado D, Van der Meer P, Jabbour A, Bondue A, Kim D, Azevedo O, Hvitfeldt Poulsen S, Yilmaz A, Jankowska EA, Algalarrondo V, Slugg A, Garg PP, Boyle KL, Yureneva E, Silliman N, Yang L, Chen J, Eraly SA, Vest J, Maurer MS. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025 Jan 02; 392(1):33-44. PMID: 39213194.

Published on 8/13/2024

Conceição I, Berk JL, Weiler M, Kowacs PA, Dasgupta NR, Khella S, Chao CC, Attarian S, Kwoh TJ, Jung SW, Chen J, Viney NJ, Yu RZ, Gertz M, Masri A, Cruz MW, Coelho T. Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform. J Neurol. 2024 Oct; 271(10):6655-6666. PMID: 39138650.